The estimated Net Worth of Peter Ordentlich is at least $420 mil dollars as of 15 February 2023. Peter Ordentlich owns over 25,000 units of Syndax Pharmaceuticals Inc stock worth over $319,281 and over the last 8 years he sold SNDX stock worth over $100,471. In addition, he makes $0 as Chief Scientific Officer at Syndax Pharmaceuticals Inc.
Peter has made over 8 trades of the Syndax Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 25,000 units of SNDX stock worth $173,750 on 15 February 2023.
The largest trade he's ever made was exercising 29,972 units of Syndax Pharmaceuticals Inc stock on 23 November 2020 worth over $92,314. On average, Peter trades about 9,150 units every 162 days since 2017. As of 15 February 2023 he still owns at least 17,428 units of Syndax Pharmaceuticals Inc stock.
You can see the complete history of Peter Ordentlich stock trades at the bottom of the page.
Dr. Peter Ordentlich Ph.D. serves as Chief Scientific Officer of the Company. Dr. Ordentlich previously served as our Chief Technical Officer from November 2013 to August 2016, our Vice President, Translational Medicine from January 2012 to October 2013, our Executive Director, Translational Science from January 2011 to December 2011, and our Director, Scientific Affairs and Strategic Alliances from January 2008 to December 2010. Prior to founding the company, Dr. Ordentlich was a scientist at the Salk Institute for Biological Studies, a biological research non-profit organization. He also spent five years as a research scientist at X-Ceptor Therapeutics, Inc., a drug discovery company, which was acquired by Exelixis, Inc. Dr. Ordentlich received a B.A. in Biochemistry and a Ph.D. in Immunology from the University of Pennsylvania.
Peter Ordentlich is 51, he's been the Chief Scientific Officer of Syndax Pharmaceuticals Inc since 2016. There are 10 older and 7 younger executives at Syndax Pharmaceuticals Inc. The oldest executive at Syndax Pharmaceuticals Inc is Dr. Michael L. Meyers M.D., Ph.D., 70, who is the Chief Medical Officer & Sr. VP.
Peter's mailing address filed with the SEC is C/O SYNDAX PHARMACEUTICALS, INC., 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM, MA, 02451.
Over the last 9 years, insiders at Syndax Pharmaceuticals Inc have traded over $1,950,406 worth of Syndax Pharmaceuticals Inc stock and bought 210,921 units worth $2,347,816 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Luke Evnin, eBriggs Morrison. On average, Syndax Pharmaceuticals Inc executives and independent directors trade stock every 50 days with the average trade being worth of $745,679. The most recent stock trade was executed by Keith A. Goldan on 14 June 2024, trading 1,250 units of SNDX stock currently worth $25,038.
syndax pharmaceuticals is a biotechnology company located at 35 gatehouse dr., building d, floor 3, waltham, ma 02451.
Syndax Pharmaceuticals Inc executives and other stock owners filed with the SEC include: